Full Press Release Details
Pioneer Dr. Stephan A. Grupp to Join Cellectis Clinical Advisory Board
NEW YORK--(BUSINESS WIRE)--September 19, 2018--Regulatory News:
Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a biopharmaceutical
company focused on developing immunotherapies based on gene-edited CAR
T-cells (UCART), today announced that Stephan A. Grupp, MD, Ph.D., a
leading pediatric oncologist at Children's Hospital of Philadelphia and
Chief of the Section of Cellular Therapy and Transplant at the
Children's Hospital of Philadelphia (CHOP) joined the Company's Clinical
Advisory Board (CAB).
Dr. Grupp is a world-renowned pediatric oncologist and cancer researcher
who initiated the first pediatric CAR T-cell trial for acute
lymphoblastic leukemia at CHOP in 2012. He also delivered CAR T-cell
therapy to the first pediatric patient in the world, paving the way for
clinical development of engineered T-cell therapies. Dr. Grupp then led
the first multicenter global study of Kymriah , which became the first
CAR-T therapy to receive approval by the U.S. Food and Drug
Administration (FDA).
"Dr. Grupp is one of the true pioneers that have marked the history of
CAR T-cell therapies whose decades of work and distinction as a true
visionary will continue to shape and inform the future of these
transformative therapies in the service of pediatric patients suffering
from cancer," said Dr. Andr Choulika, Cellectis CEO. "His experience in
pediatric oncology and groundbreaking work in CAR-T therapy will be an
enormous asset for Cellectis' CAB, and his firm belief in Cellectis'
unique approach lends additional credence to our innovative work
developing allogeneic CAR-T therapies."
"Over the course of my career, I have devoted a great deal of attention
to both autologous and allogeneic cellular therapies for pediatric
cancer patients, and I believe universal CAR-T products can change the
paradigm of cancer treatment and address urgent unmet medical needs. I
have great hopes that allogeneic CAR-T therapy can open up treatment
options for patients who don't have enough T-cells to undergo an
autologous CAR-T therapy, or who live in regions where the technology is
not available," added Dr. Grupp. "My mission throughout my career has
been to change the standard of care for pediatric patients who are
battling difficult cancers, so joining Cellectis' CAB presents a unique
opportunity to strategically guide and advance the development of these
lifesaving therapies."
Dr. Grupp is Chief of the Cell Therapy and Transplant Section, Director
of the Cancer Immunotherapy Program, Director of Translational Research
for the Center for Childhood Cancer Research and Medical Director of the
Stem Cell Laboratory at CHOP, as well as an attending physician in the
Cancer Center at CHOP, where he has worked for more than two decades.
Dr. Grupp completed a pediatric residency at Boston Children's Hospital,
and a pediatric hematology/oncology fellowship at Dana-Farber Cancer
Institute and Children's Hospital. He also completed a research
fellowship in immunology at Brigham and Women's Hospital.
Dr. Grupp has published numerous papers on various therapies for the
treatment of children with cancers, including CAR T-cell therapies, and
has been honored by numerous prestigious organizations for his work,
including the American Society of Pediatric Hematology / Oncology and
American Pediatric Society.
Cellectis is a clinical-stage biopharmaceutical company focused on
developing a new generation of cancer immunotherapies based on
gene-edited T-cells (UCART). By capitalizing on its 18 years of
expertise in gene editing - built on its flagship TALEN technology and
pioneering electroporation system PulseAgile - Cellectis uses the power
of the immune system to target and eradicate cancer cells.
Using its life-science-focused, pioneering genome engineering
technologies, Cellectis' goal is to create innovative products in
multiple fields and with various target markets.
Cellectis is listed on the Nasdaq (ticker: CLLS) and on Euronext Growth
(ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com
Talking about gene editing? We do it. TALEN is a registered trademark
This press release contains "forward-looking" statements that are based
on our management's current expectations and assumptions and on
information currently available to management. Forward-looking
statements involve known and unknown risks, uncertainties and other
factors that may cause our actual results, performance or achievements
to be materially different from any future results, performance or
achievements expressed or implied by the forward-looking statements.
Further information on the risk factors that may affect company business
and financial performance is included in Cellectis' Annual Report on
Form 20-F and the financial report (including the management report) for
the year ended December 31, 2017 and subsequent filings Cellectis makes
with the Securities Exchange Commission from time to time. Except as
required by law, we assume no obligation to update these forward-looking
statements publicly, or to update the reasons why actual results could
differ materially from those anticipated in the forward-looking
statements, even if new information becomes available in the future.
VP of Communications,
Strategic Communications, 212-896-1241
VP of Corporate Strategy and Finance, 646-385-9008